2nd study testing a COVID-19 antibody drug has a setback

by on

Regeneron Pharmaceuticals said Friday that independent monitors had recommended placing on hold enrollment of the most severely ill patients—those who need intense oxygen treatment or breathing machines—because of a potential safety problem and unfavorable balance of risks and benefits.

Regeneron Pharmaceuticals said Friday that independent monitors had recommended placing on hold enrollment of the most severely ill patients—those who need intense oxygen treatment or breathing machines—because of a potential safety problem and unfavorable balance of risks and benefits.

VA:F [1.9.7_1111]
Rating: 0.0/10 (0 votes cast)
VA:F [1.9.7_1111]
Rating: 0 (from 0 votes)

Leave a Comment

Previous post:

Next post: